Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H29NO4S.ClH |
Molecular Weight | 512.06 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC=C(C=C1)C2=C(OC3=CC=C(OCCN4CCCCC4)C=C3)C5=CC=C(O)C=C5S2
InChI
InChIKey=NHSNLUIMAQQXGR-UHFFFAOYSA-N
InChI=1S/C28H29NO4S.ClH/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29;/h5-14,19,30H,2-4,15-18H2,1H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C28H29NO4S |
Molecular Weight | 475.599 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Arzoxifene (LY353381) is a synthetic, nonsteroidal ligand termed selective estrogen receptor modulator. Arzoxifene has antiestrogenic effects on the breast and endometrium, but pro-estrogenic effects on bone and lipids. Arzoxifene has been studied in the treatment of various hormone-responsive neoplasms. Its development has been discontinued.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. | 2002 Dec |
|
Arzoxifene in breast cancer. | 2002 Nov |
|
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). | 2003 |
|
Pharmacokinetics of selective estrogen receptor modulators. | 2003 |
|
Novel therapies for osteoporosis. | 2003 Apr |
|
Arzoxifene as therapy for endometrial cancer. | 2003 Aug |
|
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. | 2003 Jul |
|
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. | 2003 Mar 15 |
|
Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. | 2003 Oct 1 |
|
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. | 2003 Oct 1 |
|
Arzoxifene Eli Lilly. | 2003 Sep |
|
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. | 2003 Sep |
|
Models of breast cancer: is merging human and animal models the future? | 2004 |
|
The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. | 2004 Apr 30 |
|
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. | 2004 Aug 15 |
|
Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer. | 2004 Aug 15 |
|
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. | 2004 Mar |
|
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. | 2004 May 15 |
|
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene. | 2004 May 31 |
|
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. | 2004 Oct |
|
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs). | 2006 |
|
Estrogen receptors as therapeutic targets in breast cancer. | 2006 |
|
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. | 2006 |
|
Developments in the pharmacotherapeutic management of osteoporosis. | 2006 Aug |
|
Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator. | 2006 Jun |
|
Arzoxifene: the development and clinical outcome of an ideal SERM. | 2006 Mar |
|
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. | 2006 Oct 1 |
|
Update on bazedoxifene: a novel selective estrogen receptor modulator. | 2007 |
|
Effect of estrogens on skin aging and the potential role of SERMs. | 2007 |
|
Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. | 2007 |
|
The future of the new selective estrogen receptor modulators. | 2007 Mar |
|
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. | 2007 Nov 1 |
|
Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene. | 2007 Nov-Dec |
|
Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. | 2007 Oct |
|
Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. | 2007 Sep |
|
The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. | 2008 Apr 22 |
|
Selective estrogen receptor modulators: an update on recent clinical findings. | 2008 Mar |
|
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. | 2009 |
|
Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro. | 2009 Apr 7 |
|
Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators. | 2009 Jan |
|
Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. | 2009 Jul |
|
Emerging drugs for postmenopausal osteoporosis. | 2009 Mar |
|
Designing the ideal selective estrogen receptor modulator--an achievable goal? | 2009 May-Jun |
|
Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. | 2009 Sep |
|
Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. | 2010 |
|
Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises. | 2010 |
|
Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? | 2010 |
|
Developing drugs to treat osteoporosis: lessons learned? | 2010 Apr |
|
Lasofoxifene: Evidence of its therapeutic value in osteoporosis. | 2010 Jun 15 |
|
Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. | 2010 May-Jun |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:30 GMT 2023
by
admin
on
Fri Dec 15 15:31:30 GMT 2023
|
Record UNII |
FU88PI0433
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1821
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
FU88PI0433
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
m2080
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID40939527
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
182133-27-3
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
DBSALT002002
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
KK-31
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
179338
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
C2460
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
300000045508
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL226267
Created by
admin on Fri Dec 15 15:31:30 GMT 2023 , Edited by admin on Fri Dec 15 15:31:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |